Health ProductsDear Healthcare Professional Letter

PROLIA (denosumab) - Association with the Risk of Atypical Femoral Fractures - For Health Professionals

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Amgen Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Health Canada Endorsed Important Safety Information on Prolia

November 16, 2012

Dear Healthcare Professional:

Subject: Association of Prolia® (denosumab) with Risk of Atypical Femoral Fracture

AMGEN Canada Inc., in consultation with Health Canada, would like to inform healthcare providers of new important safety information regarding the risk of atypical femoral fractures associated with PROLIA treatment. 

PROLIA (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Atypical femoral fractures are subtrochanteric or proximal diaphyseal fractures that may occur with little or no trauma and which may be bilateral.  Radiographic findings include simple transverse or oblique fracture with "beaking" of the cortex with diffuse cortical thickening of the proximal femoral shaft.Footnote 1 There have been no confirmed Canadian cases of atypical femoral fractures associated with PROLIA to date.  Amgen has proactively evaluated the potential for atypical femoral fractures in patients treated with PROLIA in clinical trials and the postmarketing setting.

  • Cases of atypical femoral fracture have been confirmed in patients receiving PROLIA participating in the ongoing open label extension study of the pivotal phase 3 fracture trial in postmenopausal osteoporosis (FREEDOM).
  • Events of atypical femoral fracture have occurred very rarely (<1/10,000) based on 31,266 subject years of exposure to PROLIA in bone loss studies.
  • During PROLIA treatment, healthcare professionals should advise the patients to report new or unusual thigh, hip, or groin pain. Patients presenting with such symptoms should be evaluated for an incomplete femoral fracture, and the contralateral femur should also be examined.

The Warnings and Precautions section of the PROLIA Product monograph has been updated to reflect this new information on atypical femoral fractures.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them.  Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious atypical femoral fracture or other serious or unexpected adverse reactions in patients receiving PROLIA should be reported to Amgen Canada Inc. or Health Canada.

Amgen Canada Inc.
6775 Financial Drive, Suite 100
Mississauga, Ontario  L5N 0A4
Safety Tel: 1-866-512-6436 or Fax: 1-888-264-3655
Safety e-mail: safetycanada@amgen.com

To correct your mailing address or fax number, contact Amgen Canada Inc.

To report suspected adverse reactions to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or visit the MedEffectTM Canada Web site for information on how to report.

The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffectTM Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.

For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738

A copy of this letter is available on the Health Canada Web site.  This information is also available at Amgen Canada Web Site.

Sincerely,

original signed by

Clive Ward-Able, MD
Executive Medical Director
AMGEN Canada Inc.

References:

Footnote 1

Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society of Bone and Mineral Research. J Bone Miner Res. 2010;25:2267-2294.

Return to footnote 1 referrer

 

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime